Glycomics · LC–MS/MS · orthogonal profile review

From glycan assignments to evidence that can be reviewed.

An anonymous project demonstration showing how composition assignments, chromatographic profiles, and structural claims were checked before biological interpretation. The public values and candidate labels are modified; the analytical logic is preserved.

Explore candidate profiles See biological interpretation

MS/MSidentification evidence

LC–MS + FLDorthogonal profile context

Exact massassignment consistency check

Compositionstronger than topology

Anonymousmodified display values

Analytical workflow

One evidence chain, several measurement layers.

The work combined a FragPipe-based identification stream with chromatographic and fluorescence information. Each layer answered a different question. They were not treated as interchangeable proof.

01 / IDENTIFY

Process LC–MS/MS

Raw spectra were searched in a glyco-enabled workflow. Identification outputs were carried forward with their spectral context.

02 / RECONCILE

Assemble assignments

Composition, theoretical mass, observed m/z, charge state, and retention information were placed in one review table.

03 / ALIGN

Match retention patterns

LC–MS features were aligned with fluorescence peaks after checking the systematic retention offset.

04 / QUANTIFY

Collapse duplicates

Repeated charge-state and assignment rows were collapsed at composition level before relative profile comparison.

05 / INTERPRET

Bound the claim

Cancer relevance was considered at glycan-class level. Linkage, antenna arrangement, carrier protein, and mechanism remained open.

Interactive profile comparison

Which candidates drive the profile difference?

Two representative analytical profiles are compared using modified relative abundances. Absolute signal intensity is deliberately excluded because the original profiles were acquired under non-identical loading conditions.

Order candidates by

Candidate names conceal the underlying composition. Select a row to inspect its class, direction, and interpretation limit.

CandidateProfile AProfile BΔ pp

Glycan-class profile

Candidate-level changes are summarized by broad composition class. Segment widths represent modified relative abundance.

Evidence diagnostic

Retention alignment across measurement layers

Aligned time

Diagnostic view

AI-assisted consistency screen

Automation finds conflicts. Scientific review decides what they mean.

A rule-based and AI-assisted pass checked the exported evidence package for repeated assignments, inconsistent units, retention offsets, and claims that exceeded the available structural evidence.

Repeated composition rows

Charge-state and repeated assignment rows identified before summary statistics.

Collapsed

Mass calculation

Observed m/z checked against theoretical mass and charge convention.

Consistent

Retention offset

Systematic LC–MS/FLD shift modeled before peak correspondence was interpreted.

Aligned

Relative-abundance scale

Percentage display and denominator logic checked before plotting.

Verified

Loading conditions

Absolute intensities were not compared across non-identical acquisitions.

Restricted

Structure specificity

Composition support retained; linkage and antenna topology marked as proposed.

Expert review

Boundary: the screen can find internal inconsistencies and rank evidence gaps. It cannot decide whether a drawn glycan topology is correct, whether a change is cancer-derived, or whether a candidate is clinically useful.

Biological insight add-on

Top shifted candidates, linked to cancer-relevant biology.

The links below are hypothesis-generating. They use the masked candidate’s broad glycan class and direction, not a confirmed linkage, carrier protein, pathway mechanism, or cancer subtype.

Candidate-to-biology interpretation mapClass-level evidence only

Hypothesis, not mechanism

Observed pattern

Plausible relevance

Evidence gap

Next validation step

A composition can support several structural isomers. SNFG-style drawings remain proposed until linkage and topology are supported by standards, enzymes, retention behavior, or sufficient fragmentation evidence.

Evidence decision

Useful for prioritization. Not yet a biomarker claim.

The reviewed package supports a reproducible composition-level profile comparison and a short list of cancer-relevant hypotheses. It does not establish disease specificity, mechanism, diagnostic performance, or clinical utility.

What can advance

Composition-level candidates, class shifts, aligned chromatographic evidence, and a targeted validation shortlist.

What stays provisional

Exact linkage, antenna arrangement, site or carrier assignment, and the biological source of each circulating change.

What should happen next

Repeat the comparison under harmonized loading, add cohort-level replication, and use targeted MS/MS, standards, or enzyme-based checks for the highest-priority candidates.

Scope and traceability

How to read this demonstration.

This case is based on an anonymized glycomics evidence package. Identifiers, exact compositions, exact relative abundances, acquisition details, and the disease identity are withheld or modified.

Anonymous project basis

The underlying work combined a FragPipe/MSFragger-Glyco identification stream, exported spectrum and feature evidence, LC–MS retention information, and fluorescence-derived relative profiles. The public display focuses on the review logic rather than recreating a client or patient dataset.

Important analytical limitations

The displayed profile values are modified and are not patient-level or clinical results.
Relative abundance can be compared after composition-level de-duplication; absolute intensity was not compared across non-identical loading conditions.
Composition and exact-mass consistency do not by themselves prove linkage, topology, glycoprotein carrier, or site.
Two representative profiles can illustrate a workflow but cannot establish population-level differential abundance or biomarker performance.

Selected biological context

Published experimental work supports the general relevance of high-mannose, fucosylated, branched, and sialylated glycans to cancer biology, but the direction and meaning depend on tissue, carrier, model, and cancer type. Examples include high-mannose profiling in cancer, sialoglycan–Siglec effects on NK-cell activation, and FUT8-mediated receptor fucosylation and invasion.

Public candidate labels and values are intentionally altered. The report demonstrates an evidence-review service; it is not a clinical study report.